Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. (Q52234937)

27 April 2018

title

Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. (English)

1 reference

27 April 2018

Mycobacterium avium avium

1 reference

1 reference

1 reference

1 reference

1 reference

2

1 reference

27 April 2018

Nalin Rastogi

series ordinal

3

1 reference

27 April 2018

author name string

L Horgen

series ordinal

1

1 reference

27 April 2018

publication date

1 November 1997

1 reference

27 April 2018

published in

Research in Microbiology

1 reference

27 April 2018

volume

148

1 reference

27 April 2018

issue

8

1 reference

27 April 2018

page(s)

673-681

1 reference

27 April 2018

Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS.

cites work

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Amikacin, ethambutol, and rifampin for treatment of disseminated Mycobacterium avium-intracellulare infections in patients with acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Isoniazid uptake and growth inhibition of Mycobacterium tuberculosis in relation to time and concentration of pulsed drug exposures

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Postantibiotic suppression of bacterial growth

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Continuous versus discontinuous antibiotic therapy: the role of the post-antibiotic effect and other factors

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

THE RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN.

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Growth kinetics of respiratory pathogens after short exposures to ampicillin and erythromycin in vitro

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Impact of pH and cationic supplementation on in vitro postantibiotic effect

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

The post-antibiotic effect defined by bacterial morphology

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Laboratory aspects of intermittent drug therapy

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

The Action of Penicillin on Staphylococcus: Further Observations on the Effect of a Short Exposure

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Enhanced susceptibility of gram-negative bacteria to phagocytic killing by human polymorphonuclear leucocytes after brief exposure to aztreonam

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Newly made enzymes determine ongoing cell wall synthesis and the antibacterial effects of cell wall synthesis inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Postantibiotic effects

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

Action of clofazimine on the Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

The Recovery Period following Exposure of Bacteria to Penicillins

1 reference

https://api.crossref.org/works/10.1016/S0923-2508(99)80066-7

7 January 2021

10.1016/S0923-2508(99)80066-7

Identifiers

DOI

1 reference

27 April 2018

1 reference

27 April 2018